JPWO2020115556A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020115556A5 JPWO2020115556A5 JP2021531492A JP2021531492A JPWO2020115556A5 JP WO2020115556 A5 JPWO2020115556 A5 JP WO2020115556A5 JP 2021531492 A JP2021531492 A JP 2021531492A JP 2021531492 A JP2021531492 A JP 2021531492A JP WO2020115556 A5 JPWO2020115556 A5 JP WO2020115556A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- composition
- mammal
- tumor
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862774847P | 2018-12-03 | 2018-12-03 | |
| US62/774,847 | 2018-12-03 | ||
| PCT/IB2019/001342 WO2020115556A1 (en) | 2018-12-03 | 2019-12-03 | Radioimmunoconjugates and checkpoint inhibitor combination therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022513700A JP2022513700A (ja) | 2022-02-09 |
| JPWO2020115556A5 true JPWO2020115556A5 (https=) | 2023-10-25 |
| JP2022513700A5 JP2022513700A5 (https=) | 2023-10-25 |
Family
ID=70973593
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531492A Pending JP2022513700A (ja) | 2018-12-03 | 2019-12-03 | 放射性免疫複合体とチェックポイント阻害剤の併用療法 |
| JP2021531486A Pending JP2022511471A (ja) | 2018-12-03 | 2019-12-03 | 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法 |
| JP2024193520A Pending JP2025013486A (ja) | 2018-12-03 | 2024-11-05 | 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531486A Pending JP2022511471A (ja) | 2018-12-03 | 2019-12-03 | 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法 |
| JP2024193520A Pending JP2025013486A (ja) | 2018-12-03 | 2024-11-05 | 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法 |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US20220088231A1 (https=) |
| EP (2) | EP3890789A4 (https=) |
| JP (3) | JP2022513700A (https=) |
| KR (2) | KR20210099073A (https=) |
| CN (4) | CN117482261A (https=) |
| AU (2) | AU2019394888A1 (https=) |
| BR (2) | BR112021010670A2 (https=) |
| CA (2) | CA3119917A1 (https=) |
| CL (2) | CL2021001432A1 (https=) |
| EA (2) | EA202191556A1 (https=) |
| IL (2) | IL283613A (https=) |
| MA (2) | MA54401A (https=) |
| MX (2) | MX2021006408A (https=) |
| PE (2) | PE20211286A1 (https=) |
| PH (2) | PH12021551282A1 (https=) |
| SG (2) | SG11202105112RA (https=) |
| WO (2) | WO2020115548A1 (https=) |
| ZA (1) | ZA202103429B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020142583A1 (en) * | 2019-01-04 | 2020-07-09 | Actinium Pharmaceuticals, Inc. | Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates |
| CR20210556A (es) | 2019-05-10 | 2021-12-17 | Janssen Biotech Inc | Quelantes macrocíclicos y métodos de uso de estos |
| WO2021142231A1 (en) * | 2020-01-10 | 2021-07-15 | Fusion Pharmaceuticals Inc. | Sustained immunotherapy |
| WO2021207086A1 (en) * | 2020-04-06 | 2021-10-14 | Fusion Pharmaceuticals Inc. | Tem-1-targeted radioimmunoconjugates and uses thereof |
| CN119792512A (zh) | 2020-10-14 | 2025-04-11 | 维里迪安治疗公司 | 用于治疗甲状腺眼病的组合物和方法 |
| US20250275946A1 (en) * | 2021-02-02 | 2025-09-04 | Unm Rainforest Innovations | Combination therapy for the treatment of cancer |
| US11541134B1 (en) | 2021-08-02 | 2023-01-03 | Rayzebio, Inc. | Stabilized compositions of radionuclides and uses thereof |
| TW202320850A (zh) | 2021-08-10 | 2023-06-01 | 美商維里迪恩醫療股份有限公司 | 用於治療甲狀腺眼病之組合物、劑量及方法 |
| US20250339571A1 (en) * | 2021-08-27 | 2025-11-06 | Actinium Pharmaceuticals, Inc. | Radioimmunoconjugates targeting phosphatidylserine for use in the treatment of cancer |
| CA3233733A1 (en) * | 2021-09-29 | 2023-04-06 | National Research Council Of Canada | Egfrviii-targeted compounds and uses thereof |
| TW202325344A (zh) * | 2021-11-02 | 2023-07-01 | 加拿大商融合製藥公司 | 治療癌症之方法 |
| CA3249955A1 (en) * | 2022-01-28 | 2023-08-03 | Fusion Pharmaceuticals Inc. | Polytherapy based on radiopharmaceuticals targeting NTSR1 and DNA damage response inhibitors |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5053503A (en) * | 1989-02-17 | 1991-10-01 | Centocor | Chelating agents |
| CA2110799A1 (en) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Microbially-produced antibody fragments and their conjugates |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| US7736651B1 (en) * | 2000-11-24 | 2010-06-15 | Sloan-Kettering Institute For Cancer Research | Alpha emitting constructs and uses thereof |
| ES2408704T3 (es) * | 2005-01-05 | 2013-06-21 | Biogen Idec Ma Inc. | Moléculas de unión a Cripto |
| US7612178B2 (en) * | 2006-03-28 | 2009-11-03 | Biogen Idec Ma Inc | Anti-IGF-1R antibodies and uses thereof |
| WO2011060233A1 (en) * | 2009-11-11 | 2011-05-19 | The Trustees Of The University Of Pennsylvania | Anti-tem1 antibodies and uses thereof |
| ES2978177T3 (es) * | 2009-12-02 | 2024-09-06 | Immunomedics Inc | Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer |
| GB201120779D0 (en) | 2011-12-02 | 2012-01-11 | Immodulon Therapeutics Ltd | Cancer therapy |
| GB201403875D0 (en) * | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| SI3134127T1 (sl) * | 2014-04-25 | 2020-06-30 | Rinat Neuroscience Corp. | Konjugati zdravil s protitelesi z visoko stopnjo zdravila |
| US10092645B2 (en) | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| EP3280439A1 (en) * | 2015-04-07 | 2018-02-14 | INSERM - Institut National de la Santé et de la Recherche Médicale | Anti-pd-l1 immunotoxin for use in therapy |
| US10702526B2 (en) * | 2015-04-20 | 2020-07-07 | Effector Therapeutics Inc. | Inhibitors of immune checkpoint modulators and related methods |
| WO2016172249A1 (en) * | 2015-04-20 | 2016-10-27 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| EP3303398A1 (en) * | 2015-05-29 | 2018-04-11 | Merrimack Pharmaceuticals, Inc. | Combination cancer therapies |
| ES2875747T3 (es) * | 2016-01-11 | 2021-11-11 | Univ Leland Stanford Junior | Proteínas quiméricas y métodos de inmunoterapia |
| EP3202788A1 (en) | 2016-02-05 | 2017-08-09 | MediaPharma S.r.l. | Endosialin-binding antibody |
| TWI755395B (zh) * | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | 抗-pd-1抗體與輻射治療癌症之組合 |
| US11633506B2 (en) * | 2016-07-18 | 2023-04-25 | Wisconsin Alumni Research Foundation | Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies |
| EP3496707A4 (en) | 2016-08-09 | 2020-03-25 | Angimmune, LLC | Treatment of cancer using a combination of immunomodulation and check point inhibitors |
| WO2018038680A1 (en) * | 2016-08-24 | 2018-03-01 | Scinopharm Taiwan, Ltd. | Processes for preparing olaparib |
| KR20190053909A (ko) * | 2016-09-16 | 2019-05-20 | 바이오노믹스 리미티드 | 항체와 체크포인트 면역 억제제의 병용 요법 |
| BR112019011794A2 (pt) * | 2016-12-12 | 2019-10-29 | Daiichi Sankyo Co Ltd | composição farmacêutica, e, método terapêutico. |
| EP3585436A1 (en) * | 2017-02-24 | 2020-01-01 | Bayer AS | Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor |
| KR102612882B1 (ko) * | 2017-05-05 | 2023-12-11 | 센터 포 프로브 디벨롭먼트 앤드 커머셜리제이션 | 이관능성 킬레이트 및 그의 용도의 약동학적 증진 |
| CA3062538A1 (en) * | 2017-05-05 | 2018-11-08 | Fusion Pharmaceuticals Inc. | Igf-1r monoclonal antibodies and uses thereof |
| US10093741B1 (en) * | 2017-05-05 | 2018-10-09 | Fusion Pharmaceuticals Inc. | IGF-1R monoclonal antibodies and uses thereof |
| JP2020533002A (ja) * | 2017-09-13 | 2020-11-19 | ラディミューン セラピュティックス， インク．Ｒａｄｉｍｍｕｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | メラニン抗体及びその使用 |
| CN111372613A (zh) * | 2017-11-22 | 2020-07-03 | 诺帝克纳诺维科特公司 | 放射免疫缀合物与其他药物联合治疗非霍奇金淋巴瘤 |
| CA3130747A1 (en) * | 2019-02-21 | 2020-08-27 | Bayer Aktiengesellschaft | Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates |
-
2019
- 2019-12-03 EA EA202191556A patent/EA202191556A1/ru unknown
- 2019-12-03 US US16/619,433 patent/US20220088231A1/en active Pending
- 2019-12-03 MX MX2021006408A patent/MX2021006408A/es unknown
- 2019-12-03 SG SG11202105112RA patent/SG11202105112RA/en unknown
- 2019-12-03 MX MX2021006407A patent/MX2021006407A/es unknown
- 2019-12-03 CN CN202311139310.7A patent/CN117482261A/zh active Pending
- 2019-12-03 CN CN202510572446.XA patent/CN120393061A/zh active Pending
- 2019-12-03 AU AU2019394888A patent/AU2019394888A1/en active Pending
- 2019-12-03 PE PE2021000815A patent/PE20211286A1/es unknown
- 2019-12-03 MA MA054401A patent/MA54401A/fr unknown
- 2019-12-03 EP EP19892173.6A patent/EP3890789A4/en active Pending
- 2019-12-03 JP JP2021531492A patent/JP2022513700A/ja active Pending
- 2019-12-03 BR BR112021010670-7A patent/BR112021010670A2/pt unknown
- 2019-12-03 CN CN201980079758.XA patent/CN113474014A/zh active Pending
- 2019-12-03 CA CA3119917A patent/CA3119917A1/en active Pending
- 2019-12-03 BR BR112021010799-1A patent/BR112021010799A2/pt not_active Application Discontinuation
- 2019-12-03 PE PE2021000808A patent/PE20211961A1/es unknown
- 2019-12-03 SG SG11202105192WA patent/SG11202105192WA/en unknown
- 2019-12-03 EA EA202191557A patent/EA202191557A1/ru unknown
- 2019-12-03 KR KR1020217020517A patent/KR20210099073A/ko not_active Ceased
- 2019-12-03 KR KR1020217020519A patent/KR20210099074A/ko not_active Ceased
- 2019-12-03 WO PCT/IB2019/001292 patent/WO2020115548A1/en not_active Ceased
- 2019-12-03 CA CA3119915A patent/CA3119915A1/en active Pending
- 2019-12-03 MA MA054399A patent/MA54399A/fr unknown
- 2019-12-03 WO PCT/IB2019/001342 patent/WO2020115556A1/en not_active Ceased
- 2019-12-03 AU AU2019393257A patent/AU2019393257A1/en active Pending
- 2019-12-03 US US16/619,432 patent/US11446401B2/en active Active
- 2019-12-03 JP JP2021531486A patent/JP2022511471A/ja active Pending
- 2019-12-03 CN CN201980079705.8A patent/CN113164632A/zh active Pending
- 2019-12-03 EP EP19893184.2A patent/EP3890790A4/en active Pending
-
2021
- 2021-05-20 ZA ZA2021/03429A patent/ZA202103429B/en unknown
- 2021-05-28 PH PH12021551282A patent/PH12021551282A1/en unknown
- 2021-05-28 PH PH12021551237A patent/PH12021551237A1/en unknown
- 2021-06-01 CL CL2021001432A patent/CL2021001432A1/es unknown
- 2021-06-01 CL CL2021001433A patent/CL2021001433A1/es unknown
- 2021-06-01 IL IL283613A patent/IL283613A/en unknown
- 2021-06-01 IL IL283598A patent/IL283598A/en unknown
- 2021-06-02 US US17/337,357 patent/US20210290789A1/en active Pending
- 2021-06-02 US US17/337,358 patent/US20210290788A1/en active Pending
-
2022
- 2022-08-15 US US17/819,911 patent/US20230270895A1/en not_active Abandoned
-
2024
- 2024-11-05 JP JP2024193520A patent/JP2025013486A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020518674A5 (https=) | ||
| JPWO2020115556A5 (https=) | ||
| EP3548515B1 (en) | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging | |
| US11970542B2 (en) | Bispecific antibodies specific for treating hematological malignancies | |
| JP2020518673A5 (https=) | ||
| US20120141372A1 (en) | RS7 Antibodies | |
| JP2025039567A (ja) | 二重特異性結合因子およびその使用 | |
| JP2020507571A (ja) | 免疫ｐｅｔイメージングのための放射標識抗ｌａｇ３抗体 | |
| CN1675245A (zh) | 人源化单克隆抗体hPAM4 | |
| PL216208B1 (pl) | Zastosowanie kompozycji leczniczej zawierającej niesprzężone i sprzężone przeciwciała w immunoterapii nowotworów złośliwych i choroby autoimmunizacyjnej | |
| BRPI0607486B1 (pt) | Anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos. | |
| JP2021514649A (ja) | ヒトｐｄ−ｌ１結合免疫グロブリン | |
| US20240010744A1 (en) | Humanized anti-cd45 antibodies | |
| CN112533952B (zh) | 治疗疾病或病况的组合物及其用途 | |
| TW201627286A (zh) | 放射性醫藥複合物 | |
| EP2497501B1 (en) | Radionuclides for medical use | |
| CN114555132A (zh) | 放射性金属标记抗体的制造方法 | |
| Song et al. | Bismuth-213 radioimmunotherapy with C595 anti–MUC1 monoclonal antibody in an ovarian cancer ascites model | |
| Caligiuri et al. | Immunotherapeutic approaches for hematologic malignancies | |
| US20220378956A1 (en) | Trivalent Radioisotope Bio-Targeted Radiopharmaceutical, Methods Of Preparation And Use | |
| JP7836270B2 (ja) | 抗ｄｏｔａ／抗腫瘍抗原二重特異性抗体による事前標的化放射免疫治療のためのｄｏｔａ－ハプテン組成物 | |
| Schubert et al. | Novel tumor pretargeting system based on complementary l-configured oligonucleotides | |
| EP4665410A1 (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
| Roncali et al. | Current landscape and future directions of targeted-alpha-therapy for glioblastoma treatment | |
| WO2024055040A2 (en) | Humanized anti-cd45 antibodies |